NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HALO stock has decreased by 1.3% and is now trading at $17.99. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics.

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.06. The biopharmaceutical company earned $53.70 million during the quarter, compared to the consensus estimate of $55.69 million. Halozyme Therapeutics had a negative net margin of 36.86% and a negative return on equity of 33.71%. Halozyme Therapeutics's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.01) earnings per share. View Halozyme Therapeutics' earnings history.

Halozyme Therapeutics issued an update on its FY20 earnings guidance on Monday, February, 24th. The company provided EPS guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus estimate of $0.59. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.15 million.

6 Wall Street analysts have issued twelve-month price targets for Halozyme Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they expect Halozyme Therapeutics' stock price to reach $25.33 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View analysts' price targets for Halozyme Therapeutics.

Press coverage about HALO stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutHalozyme Therapeutics.

Halozyme Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 13,870,000 shares, an increase of 7.9% from the February 13th total of 12,850,000 shares. Based on an average daily volume of 1,580,000 shares, the short-interest ratio is presently 8.8 days. Approximately 10.7% of the shares of the company are short sold. View Halozyme Therapeutics' Current Options Chain.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $17.99.

Halozyme Therapeutics has a market capitalization of $2.48 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. View additional information about Halozyme Therapeutics.

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]